Hexarelin
PerformanceAlso known as: Examorelin, EP 23905, MF-6003
Hexarelin is a research compound not approved for human use. For informational purposes only.
Overview
Hexarelin is a potent synthetic hexapeptide GHRP (Growth Hormone-Releasing Peptide) that stimulates GH release via the ghrelin receptor. It produces among the highest GH pulses of any GHRP, but also elevates cortisol and prolactin — a trade-off that distinguishes it from more selective options like Ipamorelin.
Research Summary
Hexarelin produces dose-dependent GH release significantly greater than GHRP-6 or Ipamorelin. It also has direct cardioprotective effects via CD36 receptor binding, independent of GH — making it unique among GHRPs. Studies show protection from ischemic cardiac injury and myocardial fibrosis reduction in animal models. Desensitization occurs with chronic continuous use.
Dosing Range
low
50mcg
moderate
100mcg
high
200mcg
Units: mcg · Frequency: 1–3x daily (cycling recommended to prevent desensitization)
Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.
Administration Routes
Reconstitution Notes
Reconstitute with bacteriostatic water. Typical concentration: 2mg per 2mL BAC water. Refrigerate. Stable 28 days.Step-by-step reconstitution guide →
Reported Side Effects
- Cortisol elevation
- Prolactin elevation
- Water retention
- Increased appetite
- Fatigue
- Desensitization with prolonged continuous use
Research Papers
Community Experiences
Aggregated from public forums. Anecdotal — not clinical evidence.
Community protocols on hexarelin cycling and managing desensitization.
View original threadOverview
Hexarelin is the most potent GHRP in common research use. Its GH release exceeds that of GHRP-2, GHRP-6, and Ipamorelin at equivalent doses. However, this potency comes with a less favorable hormonal profile — notable cortisol and prolactin co-elevation and faster receptor desensitization.
Cardiac Research
What sets Hexarelin apart from other GHRPs is its direct cardiac action. It binds CD36 receptors on cardiac tissue independently of GH, showing:
- Reduction in myocardial fibrosis
- Protection from ischemic injury
- Improved cardiac output in GH-deficient models
This cardiac pathway is separate from GHS-R1a signaling, meaning it persists even after GH receptor desensitization.
Desensitization Management
Continuous Hexarelin use leads to GH receptor downregulation within weeks. Common strategies:
- 5-days-on / 2-days-off cycles
- 4 weeks on / 2 weeks off longer cycles
- Using Hexarelin as a short-term "blast" rather than chronic protocol
Combining with a GHRH like CJC-1295 may partially offset desensitization by working through a different receptor pathway.
Want to calculate your dose? Use the dosing calculator →